Abstracts A189 perspective, more research is needed to identify the reasons for augmentation in children and adolescents with ADHD (e.g., duration of effect, titration) and to examine patterns of medication taking throughout the day. OBJECTIVES: Poor continuity of care occurs when patients do not follow-up after being discharged from the hospital. In bipolar disorder problems with continuity of care and medication adherence may lead to expensive relapses. The objectives of this research were threefold: 1) examine the frequency of poor continuity of care for individuals with bipolar disorder; 2) identify the predictors of poor continuity of care; and 3) evaluate the potential increased psychiatric hospitalization costs. METHODS: Premier linked their PerspectiveTM Comparative Database (PCD), the largest, most detailed, U.S. hospital database, with the administrative claims from a large managed care organization. We identifi ed 319 individuals who had a primary discharge diagnosis of bipolar disorder in the PCD and who maintained continuous eligibility for the 60 days prior and the 180 days following the hospitalization. Good continuity of care was operationally defi ned as the presence of a psychiatric visit in the 60 days following discharge. Propensity scores were used to correct for background differences between patients with good continuity of care and patients with poor continuity of care. RESULTS: A total of 34.5% of individuals had poor continuity of care. Prior to discharge, individuals who would later have poor continuity of care could be identifi ed. Some variables that independently predicted later poor continuity of care included no psychotherapy visits, no psychiatric visits, substance use diagnoses, and psychiatric hospitalizations. After correcting for background differences, patients with poor continuity of care had reduced mood stabilizer use (94 vs. 116 days, p 0.008) and twice the psychiatric hospitalization charges ($10,027 vs. $4,892, p 0.03). CONCLU-SIONS: One in three individuals with bipolar disorder did not have a psychiatric follow-up visit after discharge from the hospital. This poor continuity of care appears to lead to decreased medication adherence and increased psychiatric hospitalizations. An effective, targeted intervention could potentially prevent relapses and reduce health care costs.
1 i3 Innovus, Ann Arbor, MI, USA, 2 Shire Pharmaceuticals, Wayne, PA, USA, 3 i3 Innovus, Eden Prairie, MN, USA OBJECTIVES: This research examines the relationship of ethnicity and income with attention-defi cit hyperactivity disorder (ADHD) treatment patterns among subjects on medications of different durations. METHODS: Claims of newly treated ADHD subjects, aged 6 years, initially treated with stimulants, and continuously enrolled in a US commercial health plan 6 months prior and 12 months after their fi rst prescription (January 1, 2004 "C September 30, 2006 were studied. Subjects took short-(SAS) intermediate-(IAS) or long-acting (LAS) stimulant medication for ADHD. Persistence was defi ned as the number of days on initial therapy. Adherence was defi ned as the number of days of initial therapy divided by persistent days. Differences in mean persistence and adherence, dosing, switching and augmentation among ethnicities (non-Hispanic Caucasians [NHC] , Hispanics [H] and African Americans [AA]) and among income levels were assessed. RESULTS: Among children on LAS (n 12,796), NHC had the highest mean adherence (0.56) and the longest mean persistence (251 days) (p 0.0001 among groups), while AA had the shortest persistence (222 days) and the lowest adherence (0.46) (p 0.0001 among groups). Similarly, among adults receiving LAS (n 8422), NHC had the highest adherence (0.58) and the longest persistence (225 days). Persistence was again shortest among AA (194 days; p 0.037 among groups), while adherence was equally low for AA and H (0.52; p 0.002 among groups). Within treatment groups of different durations, the propensity of subjects to change dose, switch or augment their medication varied according to ethnicity. While no signifi cant relationship between race/ethnicity and either adherence or persistence was found among children or adults receiving SAS or IAS, the IAS and LAS groups showed greater persistence and adherence with increased income levels in some subjects. CONCLUSIONS: Persistence and adherence to stimulant medications differed by race/ethnicity and income. This may have implications for the optimal management of ADHD.
PMH88 A SYSTEMATIC EVALUATION OF PUBLISHED LITERATURE TO ASSESS BURDEN OF TREATMENT-RESISTANT DEPRESSION
Cyr P y 1 , Bockstedt L 2 , Olchanski N 1 , Halseth M 2 , Partlow K 3 , Lindeke C 2 , Handke B 2 , Goss T 3 1 Boston Healthcare Associates, Inc, Boston, MA, USA, 2 Medtronic Neuromodulation, Fridley, MN, USA, 3 Boston Healthcare Associates, Inc, Washington, DC, USA BACKGROUND: Treatment-resistant depression (TRD) is severely disabling with no treatments proven to provide sustainable benefi t when multiple medications, psychotherapy, and electroconvulsive therapy fail. (Malone, 2008) . OBJECTIVES: The perform a systematic review of published literature to evaluate recent health economics and outcomes research related to TRD to inform future research initiatives. METHODS: English language citations in PubMed and Cochrane Library from January 1, 2000-October 1, 2008 were systematically reviewed. Standard search terms defi ned disease states (including TRD, severe depression (SD), chronic depression (CD), major depressive disorders (MDD), and suicidality); interventions (deep brain stimulation, electroconvulsive therapy, transcranial magnetic stimulation and vagus nerve stimulation); and outcomes (treatment outcomes, presenteeism, symptom burden, resource utilization, productivity, cost, economics, and quality of life(QOL)). RESULTS: Initial searches yielded 8811 citations, narrowed to 5626 using date and language criteria. Title review further narrowed literature (reasons: not related to depression 70%, clinical trials of antidepressant medications 20%, and review/case studies 10%), resulting in 411 unique abstracts for review and forty publications for abstraction. Clinical studies were most frequent (n 16) and economic models least frequent (n 3); a majority (n 22) reported a U.S. patient population. Thirteen publications reported on TRD, thirteen on MDD, and six reported on a "general depression" population. Reported defi nitions of TRD varied greatly (one medication failure (n 2), two medication failures (n 6), HAM-D score (n 3), diagnosis/treatment algorithm (n 1), not defi ned (n 1)). HAM-D (n 12) and MADRS (n 9) were the most frequently reported clinical outcomes measures. Cost outcomes were discussed in thirteen reports (direct costs (n 11), indirect costs (n 2)). CONCLU-SIONS: Defi nitions of TRD or CD reported in the literature vary substantially, and studies examining productivity of patients were confi ned to generic depression or MDD populations and would not be directly comparable to a CD or TRD population. Additional research is necessary to better defi ne the cost and patient burden of TRD. 2%. General Practitioners were the primary point of diagnosis and source of treatment, even though this statistic varied between the countries. CONCLUSIONS: Prevalence of insomnia appears to be substantial in the studied European nations, with France bearing the most burden (one-in-fi ve and one-in-three males and females respectively in France suffered from this condition). Prevalence peaked among the 45-64 age-group across the countries. Females had substantially higher disease burden across the countries, amounting to as much as 1.5 to 2 times more than their male counterparts in certain age groups.
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PND2 CHRONIC MIGRAINE CRITERIA AND THEIR EFFECTS ON GLOBAL PREVALENCE ESTIMATES: A SYSTEMATIC REVIEW
Natoli JL J 1 , Manack A 2 , Dean BB 1 1 Cerner LifeSciences, Beverly Hills, CA, USA, 2 Allergan, Inc., Irvine, CA, USA OBJECTIVES: The defi nition of chronic migraine (CM), as opposed to episodic migraine, has evolved over 20 years of clinical study. This systematic review summarized population-based studies reporting CM prevalence and examined how variations in defi nitions affected estimates. METHODS: We conducted a systematic search of PubMed, Cochrane, and EMBASE. Search terms included chronic migraine, transformed migraine, chronic headache, and prevalence. We included populationbased studies in adults and mixed adults/adolescents that estimated CM prevalence (or provided information to calculate estimates). We defi ned chronicity as a minimum headache frequency of 10 per month or reported "daily" headache. Where equivalent, we combined diagnostic criteria and defi nitions. Findings were qualitatively summarized. RESULTS: Sixteen publications representing 12 unique studies were identifi ed.
Diagnostic criteria were heterogeneous and included defi nitions based on International Classifi cation for Headache Disorders (ICHD) guidelines, Silberstein-Lipton criteria, and various investigator-defi ned frequency-based classifi cations. Thus, defi nitions varied from relatively strict criteria ( 15 days/month of migraine) to more liberal criteria (history of migraine and 15 days/month of headache). Prevalence of CM was 0%-5.1%, with estimates typically in the range of 1.4%-2.2%. Seven studies used criteria of history of migraine and 15 days/month of headache (or equivalent), with prevalence of 0.9%-5.1%. Three studies used criteria of 15 days/month of migraine (or equivalent), with prevalence of 0%-0.7%. Two studies stated that the condition was transformed migraine or chronic migraine (without specifi c criteria), with prevalence of 1.6% and 4.1%. Prevalence varied by WHO region and gender. CONCLU-SIONS: CM prevalence estimates are infl uenced by specifi c defi nitions employed. Using the strictest criteria, prevalence was well under 1%; with a less restrictive defi nition, prevalence was higher, 1%-5%. With these variations, it is diffi cult to compare results across regions and explore temporal trends. Future studies on CM would benefi t from an ICHD consensus diagnosis that is clinically appropriate and operational in large-scale epidemiological studies.
PND3
PREVALENCE OF ALZHEIMER'S DISEASE AND RELATED DEMENTIA AND THE CO-EXISTING CONDITIONS IN MANAGED CARE ORGANIZATIONS
Liu M 1 , Ganguly R 2 1 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2 GlaxoSmithKline, Research Triangle Park, NC, USA OBJECTIVES: Prevalence data of Alzheimer's disease and related dementia (ADRD) in managed care organizations (MCO) is old and very few data on the prevalence of the co-existing conditions. This study aims at investigating the rates and the trend of the prevalence of ADRD and the co-existing conditions in MCO over an eleven-year period. METHODS: Data are drawn from the Ingenix Impact National Managed Care Database (Impact Database). The study time period is 1997-2007. Annual prevalence of ADRD and two common co-existing conditions (type II diabetes and congestive heart failure) are calculated among those aged 50 and those aged 65. Prevalence of the co-existing conditions among ADRD patients are compared to the prevalence among the general population in the same age group. Data extraction and prevalence calculations are performed in SAS 9.1. RESULTS: From 1997 to 2001, prevalence of ADRD increased dramatically among those aged 50 and aged 65. Prevalence of ADRD starts to level off during 2005-2007 in both age groups. For the two co-morbid conditions that are investigated, 1) prevalence of diabetes is 2.3 times higher in ADRD patients than in the general population, prevalence of congestive heart failure is 5 times higher; and 2) during 1997-2007, prevalence of both co-morbid conditions among ADRD patients are constantly increasing, whereas the prevalence in the general population are variant. CONCLUSIONS: In this study, prevalence estimates of ADRD are consistent with the literature. The fi nding that the prevalence of ADRD starts to level off since 2005 may indicate that for persons under the care of MCO, the underdiagnose of ADRD may drop to a certain level in recent years. The substantially higher prevalence of co-morbid conditions among ADRD patients and its constantly increasing trend may pose both challenge and opportunity to MCO managers in their strategies for containing costs.
PND4
RATE OF DISEASE PROGRESSION AMONG PATIENTS WITH PARKINSON'S DISEASE IN SINGAPORE
Zhao YJ 1 , Tan LC 2 , Seah SH 2 , Lau PN 2 , Au WL 2 , Li SC 3 , Luo N 1 , Wee HL 1 1 National University of Singapore, Singapore, Singapore, 2 National Neuroscience Institute, Singapore, Singapore, 3 University of Newcastle, Callaghan, Australia OBJECTIVES: Worldwide, data on the long term prognosis of Parkinson's disease (PD) are limited, particularly in South-east Asia. This study was carried out to investigate the time taken to transit between Hoehn & Yahr (H&Y) stages among patients with PD in Singapore. METHODS: Patients were recruited from a tertiary neuroscience clinic in Singapore. Both patients' clinical and demographic information were obtained from hospital's database. Time-to-transition was computed using Kaplan-Meier analysis. Cox regression analysis was performed to examine the infl uence of gender, race, duration of PD and age-at-diagnosis on time-to-transition. RESULTS: A total of 695 patients (mean age: 65.3, male: 58%) consented to participate in the study. Using Kaplan-Meier analysis, the time-to-transition from H&Y stage 1 to 2, from 2 to 2.5, from 2.5 to 3 were 22.3, 52.9 and 30.3 months, respectively. Time-totransition from stage 3 to 4, and from stage 4 to 5 were 27.4 and 30.0 months, respectively. In Cox regression analysis, younger-onset (age at diagnosis 83.6 as reference group, p 0.006; age at diagnosis 56.1, f 1.713, p 0.011) and shorter PD duration (duration 14.7 as reference group, p 0.002; duration 4.9, f 2.188, p 0.001; duration 7.5, f 1.443, p 0.030) predicted longer time-totransition from stage 2 to 2.5. Shorter PD duration (duration 22.8, p 0.021) similarly predicted longer duration from stage 4 to 5. CONCLUSIONS: To the best of our knowledge, this is the fi rst study to report on disease progression using time-totransition between various H&Y stages. Our fi ndings were similar from current literature in that younger-onset patients took longer to reach advanced stages. However, unlike published literature, disease progression was not slower among female compared to male patients in our study. This could be a real difference or could be due to different ways of measuring disease progression. The data are thus interesting and worth further exploration. These information are also important to clinicians to help improve patient management.
